Epigenetic Biomarker Discovery in HPV related HNSCC

HPV 相关 HNSCC 中表观遗传生物标志物的发现

基本信息

批准号：
8479498
负责人：
Joseph A Califano
金额：
$ 38.48万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-04-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8479498
关键词：
Affect Age Area Biological Assay Biological Markers Blood Body Fluids Cancer Control Cervix carcinoma Characteristics Clinical DNA DNA Methylation Data Detection Development Diagnostic Diagnostic Neoplasm Staging Disease Epidemiology Epigenetic Process Gender Genetic Genome Genomics HPV-High Risk Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Human Papillomavirus Incidence Malignant Neoplasms Measurement Methods Methylation Microscopic Modality Pap smear Pathologic Patients Performance Plasma Population Premalignant Recurrence Resolution Risk Saliva Salivary Sampling Secondary Prevention Smoking Staging Techniques Testing United States Validation alcohol exposure base bisulfite case control cost effective design epigenetic marker malignant mouth neoplasm malignant oropharynx neoplasm multiplex detection novel novel strategies oral premalignancy performance tests population based pre-clinical prognostic public health relevance response screening tobacco exposure treatment response viral DNA

项目摘要

DESCRIPTION (provided by applicant): High risk human papilloma virus related head and neck squamous cell carcinoma (HPVHNSCC) incidence is rapidly increasing, and will soon surpass the incidence of cervical carcinoma in the US. There are no effective ways to detect preclinical or early HPVHNSCC, screen populations at increased risk for HPVHNSCC development, or even assay for microscopic persistence of HPVHNSCC after therapy. However, epigenetic alterations have been detected in body fluids from premalignant and early stage cancers and multiplex tests have shown promise for identification of patients with oral premalignancy. Our primary hypothesis is that multiplex testing of plasma and salivary rinses based on HPVHNSCC specific epigenetic alterations combined with high risk HPV DNA presence has potential as useful test for presence of HPVHNSCC. This project will serve as a discovery and diagnostic validation biomarker development trial for HPVHNSCC detection with potential application for assessment of disease response and development of a population based screening test.

描述（由申请人提供）：高风险人类乳头瘤病毒相关的头部和颈部鳞状细胞癌（HPVHNSCC）的发病率正在迅速增加，并且很快将超过美国宫颈癌的发生率。没有有效的方法来检测临床前或早期HPVHNSCC，筛查群体的开发风险增加，甚至在治疗后HPVHNSCC的微观持久性的测定。然而，在预抗癌和早期癌症的体液中已经检测到表观遗传改变，多重测试显示出有望鉴定口服预调查患者。我们的主要假设是，基于HPVHNSCC特异性表观遗传学变化的血浆和唾液冲洗的多重测试与高风险HPV DNA的存在相结合具有HPVHNSCC存在的有用测试。该项目将作为HPVHNSCC检测的发现和诊断验证生物标志物开发试验，并潜在地应用疾病反应和基于人群的筛查测试的发展。